Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
Authors:
- 1 July 2010
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 177 (1) , 415-423
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnnals of Oncology, 2008
- Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinomaCancer, 2008
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBritish Journal of Cancer, 2008
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsBritish Journal of Cancer, 2008
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsBritish Journal of Cancer, 2006
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000